Retinal Pigment Epithelial Characteristics in Eyes With Neovascular Age-related Macular Degeneration Following Long-term Treatment With Anti Neovascular Endothelial Growth Factor
NCT ID: NCT03679156
Last Updated: 2018-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
18 participants
OBSERVATIONAL
2016-05-30
2017-04-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis.
Methods:
18 patients (18 eyes) with neovascular AMD were recruited subsequent to completion the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range: 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as-needed \[pro re nata (PRN)\]. Functional and morphological changes were assessed using spectral domain optical coherence tomography (SD-OCT).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imaging of the Angiofibrotic Switch in Neovascular AMD
NCT03838679
Non-invasive Optical Angiography in Age-related Macular Degeneration
NCT02521142
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
NCT06717139
The Impact of Two Strategies in the Monitoring of Exudative ARMD on the Visual Acuity (by OCT B Scan or OCT Angiography)
NCT02868086
Retinal Investigation Using Optos OCT Device
NCT06846151
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OCT
Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Inclusion and exclusion criteria corresponded to the criteria of the MANTA study
Exclusion Criteria:
* Inclusion and exclusion criteria corresponded to the criteria of the MANTA study
66 Years
98 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Hietzing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Clara Wernigg
Dr.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RPE characteristics
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.